Curonix Expands Coverage for Freedom Nerve Stimulator

Medical device company secures new reimbursement approvals for its peripheral nerve stimulation technology.

Apr. 2, 2026 at 3:48pm

Got story updates? Submit your updates here. ›

Curonix LLC, a medical technology company based in Pompano Beach, Florida, has announced expanded reimbursement coverage for its Freedom Peripheral Nerve Stimulator. The device is designed to provide pain relief for patients through targeted electrical stimulation of peripheral nerves.

Why it matters

Increased insurance coverage for innovative pain management technologies like the Freedom Stimulator can improve access and affordability for patients seeking alternatives to opioids or invasive procedures. Curonix's announcement signals progress in the adoption of advanced neuromodulation therapies.

The details

The Freedom Peripheral Nerve Stimulator is a minimally invasive device that is implanted near target nerves to deliver electrical pulses that disrupt pain signals. Curonix has secured new reimbursement approvals from several major insurance providers, making the treatment more accessible to a wider range of patients suffering from chronic pain conditions.

  • Curonix LLC announced the expanded reimbursement coverage on April 2, 2026.

The players

Curonix LLC

A leading medical technology company that develops innovative pain management solutions, including the Freedom Peripheral Nerve Stimulator.

Got photos? Submit your photos here. ›

What’s next

The expanded reimbursement coverage is expected to drive increased adoption of the Freedom Stimulator as more patients gain access to the treatment through their insurance plans.

The takeaway

The approval of broader insurance coverage for the Freedom Peripheral Nerve Stimulator represents progress in making advanced pain management technologies more accessible and affordable for patients seeking alternatives to opioids or invasive procedures.